Bcl-6
Overview
Bcl-6 (B cell lymphoma 6) is a zinc-finger transcriptional repressor essential for germinal center (GC) formation. It is the master transcription factor of both GC B cells and GC-type T follicular helper (TFH) cells. Bcl-6 expression is required for B cells to enter and persist within GCs, and for CD4⁺ T cells to differentiate into the Bcl-6⁺ CXCR5⁺ GC-TFH cells that sustain GC reactions. Its absence or suppression therefore provides a direct readout of GC disruption.
In the context of this wiki, Bcl-6 is the critical marker linking GC failure to EF pathway dominance: loss of Bcl-6⁺ cells indicates that the GC arm of humoral immunity is compromised, forcing B cell responses through the extrafollicular pathway.
Key Points from Literature
- Bcl-6⁺ GC B cells strikingly reduced in COVID-19 LNs and spleens: Multi-color immunofluorescence of post-mortem thoracic lymph nodes showed marked reduction in CD19⁺Bcl-6⁺ cells (p<0.001 vs. non-COVID controls). Splenic Bcl-6⁺ B cells were similarly reduced (p<0.01). This was evident from the earliest disease timepoint (<10 days from symptom onset) and persisted through late disease (see Kaneko2020 - GC Loss and TFH Block in COVID-19, n=11 COVID + 6 LN controls + 7 spleen controls, multi-color immunofluorescence).
- AID⁺ B cells preserved despite Bcl-6⁺ B cell loss: AID-expressing B cells were maintained in COVID-19 LNs and spleens, though diffusely distributed rather than concentrated in GC structures. This dissociation — Bcl-6 lost but AID preserved — demonstrates that B cell activation and class switch recombination continue extrafollicularly even when GC formation is abrogated (see Kaneko2020 - GC Loss and TFH Block in COVID-19).
- Bcl-6⁺ GC-TFH cells specifically depleted: The most striking T cell finding was the near-absence of CD4⁺Bcl-6⁺ GC-type TFH cells in both LNs (p<0.001) and spleens (p<0.01) of COVID-19 patients. CD4⁺CXCR5⁺ pre-GC TFH cells were present but reduced; CD4⁺ICOS⁺ TFH cells were diminished. The selective loss of Bcl-6⁺ TFH cells indicates a specific block in the final step of GC-TFH differentiation — the transition from pre-GC (Bcl-6⁻CXCR5⁺) to GC-type (Bcl-6⁺CXCR5⁺) TFH (see Kaneko2020 - GC Loss and TFH Block in COVID-19).
- Bcl-6⁺ T follicular regulatory cells also absent: Multispectral imaging with CD4/CXCR5/FOXP3/Bcl-6 showed no overlap between Bcl-6 and FOXP3 expression in COVID-19 secondary lymphoid organs, indicating the near-absence of Bcl-6⁺ T follicular regulatory cells alongside the loss of Bcl-6⁺ TFH and GC B cells (see Kaneko2020 - GC Loss and TFH Block in COVID-19).
- DN1 cells are Bcl-6-pathway associated: DN1 cells (CXCR5⁺, CD21⁺) share a near-identical transcriptome with switched memory cells and express TCF7, CXCR5, and BACH2 — hallmarks of GC transit. They contrast with DN2 cells (CXCR5⁻, T-bet⁺), which belong to the EF pathway. CD40L stimulation does not inhibit DN1 generation, consistent with GC compatibility (see Jenks2018 - DN2 B Cells and EF Pathway in SLE, RNA-seq + in vitro differentiation).
- GC loss in COVID-19 also observed peripherally in Woodruff2020: The peripheral blood EF dominance in critically ill COVID-19 patients — expanded DN2, aN, ASC populations with germline-dominant BCR repertoires — is the blood-level correlate of the tissue-level GC loss demonstrated by Kaneko2020 (see Woodruff2020 - EF B Cell Responses in COVID-19, 24-marker spectral FCM, n=10 ICU).
Contradictions & Debates
- Whether Bcl-6⁺ TFH cells are generated in milder COVID-19 is unknown — the tissue study was limited to fatal cases. Milder disease may represent a continuum with some GC formation.
- The absence of Bcl-6 in COVID-19 lymphoid tissue contrasts with dengue, where elevated CXCL13 suggests possible GC activity (though CXCL13 is not GC-specific). Whether dengue produces Bcl-6⁺ TFH cells — and whether severe dengue suppresses them — is untested.
Related Pages
Germinal Center, Extrafollicular Response, AID, CXCR5, ICOS, T-bet, TNF-alpha, Double-Negative B Cell, DN2 B Cell